INTRODUCTION {#sec1-1}
============

Upper gastrointestinal endoscopy (esophagogas troduodenoscopy or EGD) is one of the most common diagnostic and therapeutic methods of assessing upper gastrointestinal diseases.\[[@ref1][@ref2]\] Improvements in the detection of premalignant lesions, early esophageal and gastric cancers will enable organ-preserving endoscopic therapy, potentially reduce the number of advanced upper gastrointestinal cancers and offer improved prognosis.\[[@ref3]\] Furthermore, endoscopic treatment has now supplanted many surgical procedures.\[[@ref4]\] However, the presence of foam, bubbles and mucus can preclude the benefits of endoscopy, as subtle mucosal lesions could be covered.\[[@ref5]\] Previous studies have showed that \>50% of total gastric cancers in Japan were found in an early stage but probably fewer in other countries, and patients with advanced cancer suffer from poor 5-year survival rate.\[[@ref6][@ref7]\] Amin *et al*., in a study in UK reported that the diagnosis of 14% patients (18 of 129 patients presenting with gastric adenocarcinoma) was missed at first endoscopy.\[[@ref8]\] Detection of the cancer at an early stage is very important to obtain good prognosis. In screening endoscopy, the overall gastric mucosa is thoroughly observed to detect any suspicious findings for neoplasia, whereas only the presence of apparent lesions that may cause symptoms or abnormal image findings are investigated.\[[@ref9]\] One limitation of endoscopic procedure is, however, the presence of bubbles and foam in stomach and duodenum, such that it is difficult for an endoscopist to evaluate the mucosa. This will lead to decreased diagnostic accuracy, prolonged endoscopy time and decreased patient\'s tolerance.\[[@ref10]\] Therefore, diagnostic accuracy of early gastric cancer can be improved by effective premedication ingestion with a defoaming agent, before upper gastrointestinal endoscopy, for the removal of bubbles.\[[@ref11][@ref12]\]

Many studies have shown that premedication before gastroscopy will improve the total mucosal visibility scores. Simethicone has been reported as an effective defoaming agent in many trials.\[[@ref13][@ref14]\] In addition to upper endoscopy, simethicone has also been used in colonoscopy and capsule endoscopy to eliminate bubbles.\[[@ref15][@ref16]\] Meanwhile, *N*-acetylcysteine (NAC) is widely used as a mucolytic agent in respiratory diseases previously. Some studies have demonstrated that the combination of a mucolytic such as NAC with a defoaming agent offers further benefit.\[[@ref17][@ref18]\]

Although some investigators do use simethicone or NAC before the endoscopic procedure,\[[@ref17][@ref18][@ref19]\] there is a lack of systematic analysis regarding the combination of simethicone and NAC. The aim of this meta-analysis was, therefore, to assess the effectiveness of simethicone and NAC on reduction of bubbles and increasing positive findings in patients undergoing gastroscopy.

MATERIALS AND METHODS {#sec1-2}
=====================

This systematic review and meta-analysis were registered at International Prospective Register of Systematic Reviews (number CRD42018114613).

Data source and search strategy {#sec2-1}
-------------------------------

Studies were identified by a comprehensive search in the following four databases: EMBASE, PubMed, Cochrane library and Web of science database. The search was designed and performed by two authors (Li and Du) and updated until October 1, 2018. Searches were conducted by combining the following terms: ("Simethicone") OR ")dimethicone") OR ")N-acetylcysteine") and (\[")Oesophago-gastro-duodenoscopy") and ")Simethicone") OR ("gastroscopy") and ")Simethicone") OR ("Oesophago-gastro-duodenoscopy") and ")dimethicone") OR ("gastroscopy") and ")dimethicone") OR ("Oesophago-gastro-duodenoscopy") and ")N-acetylcysteine") OR ("gastroscopy") and ")N-acetylcysteine")\]) and ("premedication") and ")Oesophago-gastro-duodenoscopy") OR ")gastroscopy").

Inclusion criteria {#sec2-2}
------------------

### Type of study {#sec3-1}

The types of studies included were randomized controlled clinical trials published regardless of whether these were single blind or double blind. We did not apply any date or language restrictions.

### Types of participants {#sec3-2}

Adults who were planned for gastroscopy as part of their management plan were included. Participants who had contraindication to gastroscopy, previous history of surgical resection of the esophagus, stomach, or duodenum or required gastroscopy for urgent indications, such as suspected gastrointestinal bleeding, were all excluded.

### Types of intervention studies of simethicone or dimethicone ± NAC for preprocedure of gastroscopy were included {#sec3-3}

Since simethicone and dimethicone have a similar defoaming mechanism, we included RCTs utilizing dimethicone. Using simethicone or dimethicone alone as an intervention or in combination with NAC could be included. However, other interventions (i.e. pronase) were excluded.

### Outcome measures {#sec3-4}

At least one of the following outcomes was evaluated: (1) positive findings rate: upper gastrointestinal lesion (i.e. peptic ulcer, polyps, early upper gastrointestinal cancer); (2) mucosal visibility score: total mucosal visibility score of upper gastrointestinal tract; (3) procedure time: total time from intubation to withdrawal; and (4) rate of adverse events: frequency of adverse events (i.e., bloating).

Exclusion criteria {#sec2-3}
------------------

Exclusion criteria were as follows: (1) conference abstracts, (2) other methods of treatment as intervention measures, (3) nonrandom or uncontrolled trials, (4) not providing data on the outcome of interest, and (5) not providing adequate information to assess risk of bias (i.e., random sequence generation and allocation concealment)

Data extraction {#sec2-4}
---------------

Two authors (Du and Fu) independently performed data extraction and quality assessment, disagreements were resolved by consensus, and a third senior author (Li) was consulted when necessary. A data extraction form was predefined for data collection \[[Table 1](#T1){ref-type="table"}\], including the following entries:first author, year of publication, country, study design information, sample size, drinking time, interventions and outcomes assessed. Owing to the focus of our study, ")per protocol") treatment effects were preferred in RCTs.

###### 

Baseline characteristics of the included studies

  Author                         Year   Area        Experimental group                                                              Control group                  Drinking time (before procedure) (min)   No. of participants    Outcomes
  ------------------------------ ------ ----------- ------------------------------------------------------------------------------- ------------------------------ ---------------------------------------- ---------------------- -------------------------------------------
  Keeratichananont\[[@ref26]\]   2010   Thailand    A. Sim 133.3 mg in 60-mL water                                                  B. 60-mLwater                  15-30                                    A: 63; B: 58           TMVS, PT, PF, AEs
  Ahsan\[[@ref27]\]              2011   Iran        A. Sim 40 mg in 30-mL water                                                     B. 30-mL water                 15-30                                    A: 90; B: 83           gastric and duodenal foam/air bubbles, PT
  Asl\[[@ref17]\]                2011   Iran        A. dimethicone 100 mg in 100 water; B. Dimethicone 100+NAC600 in 100-mL water   C. 100-mL water                20 min                                   A: 37; B: 36; C: 38    TMVS
  Neale\[[@ref28]\]              2013   UK          A. Sim 2.5 mL and NAC 3 mL in 100-mL water                                      B. 100-mL water                20                                       A: 23; B: 23           TMVS evaluated as flush volume, PT
  Chang\[[@ref18]\]              2014   Taiwan      A. Sim 100 mg and NAC 200 mg in 100-mL water                                    B. Sim 100 mg in 100-mLwater   10-30                                    A: 583; B: 643         TMVS, PT, AEs
  Song\[[@ref5]\]                2016   Singapore   A. Sim 100 mg in 5-mL water                                                     B. 5-mL water                  30                                       A: 27; B: 27           TMVS, PT, PF
  Elvas\[[@ref29]\]              2016   Portugal    A. Sim 100 mg in 100-mL waterB. Sim 100 mg and NAC 600 mg in 100-mL water       C.100-mL water                 15-30                                    A: 101; B: 98; C: 98   MVS, PF, AEs
  Basford\[[@ref30]\]            2016   UK          A. Sim 60 mg and NAC 1,000 mg in 50-mL water                                    B. 50-mL water                 5-10                                     A: 41; B: 40           TMVS, PT
  Liu\[[@ref32]\]                2017   China       A. Sim 80 mg in 100-mL water                                                    B. 100-mL water                20                                       A: 1777; B: 1772       MVS, PT, PF
  Monrroy\[[@ref31]\]            2017   Chile       A. Sim 200 mg in100-mL waterB. Sim 200 mg and NAC 500 mg in 100-mL water        C. 100-mL water                20                                       A: 46; B: 46; C: 46    TMVS, PF

Sim: Simethicone; NAC: N-acetylcysteine; TMVS: Total mucosal visibility score; MVS: Mucosal visibility score; PT: Procedure time; PF: Positive findings; AE: Adverse events

Assessment for risk of bias {#sec2-5}
---------------------------

Cochrane collaboration\'s assessment tool for RCT was used to assess the risk of bias, as follows: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias.\[[@ref20]\] Summary profile of the resulting evidence was presented by using tool GRADEpro GDT online (<http://www.guidelinedevelopment.org/>) for every outcome.\[[@ref21]\] The level of evidence was classified as high, moderate, low, or very low. Evaluation of the level of evidence was done on the following domains: study design, risk of bias, inconsistency, indirectness, imprecision and publication bias.

Statistical analysis {#sec2-6}
--------------------

Cumulative meta-analyses were performed for outcomes reported, in a suitable and consistent format, by more than two studies. Data collected were divided into dichotomous and continuous variables, and risk ratio (RR) and mean difference (MD) were used as effect values, respectively. The effects of treatment on continuous variables were assessed as MD or standardized mean difference, as appropriate. Heterogeneity between studies was evaluated by using χ^2^(chi-squared) test with *P* \< 0.05 and *I*^2^statistic. *I*^2^values of 25%, 50%, and 75% were considered to correspond to low, medium and high levels of heterogeneity, respectively. A fixed-effect model was used when there was no significant heterogeneity between studies; otherwise a random-effect model was employed and sensitivity analysis was performed to explore heterogeneity.\[[@ref22]\] We did sensitivity analysis to analyze the influence of individual trials by omitting included trials one by one. 95% confidence intervals (CI) were calculated, and *P* \< 0.05 was regarded as statistically significant.\[[@ref23][@ref24]\] Statistically analyses were performed by using Review Manager (RevMan; Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

RESULTS {#sec1-3}
=======

Search results {#sec2-7}
--------------

Searches in the four databases returned a total of 1,356 papers (EMBASE = 407, PubMed = 238, Cochrane library = 320, and Web of Science database = 391). After removal of duplicates (*n* = 1142), the titles and abstracts of 214 publications were screened and 200 studies were dropped at this stage for not relevant study design (see [Figure 1](#F1){ref-type="fig"}). Full-text articles were retrieved for 14 studies for further eligibility assessment and four of them failed to meet the inclusion criteria, of which three were excluded due to poor information for methodological quality.\[[@ref13][@ref14][@ref25]\] Thus, 10 studies were included in this review.\[[@ref5][@ref17][@ref18][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32]\]

![PRISMA: flow diagram](SJG-25-218-g001){#F1}

Study characteristics {#sec2-8}
---------------------

The characteristics and data extraction of qualified studies included in the meta-analysis are summarized in [Table 1](#T1){ref-type="table"}. In total, 5,750 participants from 10 RCTs were included. The number of participants varied from 54\[[@ref5]\] to 3,549.\[[@ref32]\] All but one study\[[@ref27]\] reported age, gender, clinical priority and indication in detail. The mean age of patients ranged from 42.2\[[@ref17]\] to 63.8 years.\[[@ref30]\] Male gender spanned from 33.3%\[[@ref5]\] to 69.6%.\[[@ref28]\] There was no significant difference in age, gender, clinical priority and indication in all the studies. Among the studies, three\[[@ref5][@ref26][@ref27]\] studies compared simethicone with water, six studies\[[@ref17][@ref18][@ref28][@ref29][@ref30][@ref31]\] assessed simethicone alone or plus NAC versus water, and one\[[@ref32]\] compared simethicone alone or plus pronase with water. All interventions were taken orally with water (volume ranged from 5--100 ml) 5--30 min before gastroscopy. Five studies\[[@ref18][@ref26][@ref29][@ref31][@ref32]\] reported positive findings. Mucosal visibility scale was adopted in all studies, of which six used four-point scale,\[[@ref5][@ref17][@ref26][@ref27][@ref31][@ref32]\] two used three-point scale,\[[@ref18][@ref32]\] one used excellent/adequate/inadequate scores,\[[@ref29]\] and one used volume of flush used.\[[@ref28]\] Five studies\[[@ref26][@ref27][@ref28][@ref30][@ref32]\] focused on procedure time and four\[[@ref5][@ref26][@ref29][@ref31]\] mentioned adverse events.

The assessment for risk of bias {#sec2-9}
-------------------------------

Risk of bias of randomized controlled trials is summarized in [Table 2](#T2){ref-type="table"}. Information on the random sequence generation and allocation concealment was reported in all and nine studies except one,\[[@ref26]\] respectively. Eight RCTs were double-blind and two studies were endoscopist-blinded.\[[@ref18][@ref28]\] All but three\[[@ref5][@ref18][@ref28]\] specifically provided information on blinding of the outcome assessors. All studies reported a sample size calculation. Incomplete outcome data and selective report were not found in all studies. No other potential source of bias was apparently present in the included studies.

###### 

The risk of bias in included studies

  Study                               Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome data   Incomplete outcome data   Selective report   Other
  ----------------------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------- ------------------------- ------------------ -------
  Keeratichananont\[[@ref26]\] 2010   LR                           UR                       LR                                       LR                         LR                        LR                 LR
  Ahsan\[[@ref27]\] 2011              LR                           LR                       LR                                       LR                         LR                        LR                 LR
  Asl\[[@ref17]\] 2011                LR                           LR                       LR                                       LR                         LR                        LR                 LR
  Neale\[[@ref28]\] 2013              LR                           LR                       LR                                       UR                         LR                        LR                 LR
  Chang\[[@ref18]\] 2014              LR                           LR                       LR                                       UR                         LR                        LR                 lR
  Song\[[@ref5]\] 2016                LR                           LR                       LR                                       UR                         LR                        LR                 LR
  Elvas\[[@ref29]\] 2016              LR                           LR                       LR                                       LR                         LR                        LR                 LR
  Basford\[[@ref30]\] 2016            LR                           LR                       LR                                       LR                         LR                        LR                 LR
  Liu\[[@ref32]\] 2017                LR                           LR                       LR                                       LR                         LR                        LR                 LR
  Monrroy\[[@ref31]\] 2017            LR                           LR                       LR                                       LR                         LR                        LR                 LR

LR: Low risk of bias; UR: Unclear risk of bias

Outcomes {#sec2-10}
--------

### Positive findings {#sec3-5}

There were five studies identified.\[[@ref18][@ref26][@ref29][@ref31][@ref32]\] Among included studies, Liu *et al*.\[[@ref32]\] reported precancerous lesions and early cancer only, and others reported all upper digestive tract diseases. There were no significant differences in the rate of positive findings comparing simethicone with water (RR = 1.13, 95%CI: 0.82--1.55, *P* = 0.46) \[[Figure 2](#F2){ref-type="fig"}\]. Heterogeneity was significant (*I*^2^= 79%, *P* = 0.008) and sensitivity analyses were performed. By removing the study by Keeratichananont *et al*.,\[[@ref26]\] the heterogeneity reduced to *I*^2^= 59%. However, we could not find a difference between this study and other two studies. Sensitivity analyses were performed, and meta-analysis did not change significantly. Similar results were observed with simethicone plus NAC versus simethicone (RR = 1.02, 95%CI: 0.90-1.16, *P* = 0.71) \[[Figure 3](#F3){ref-type="fig"}\], heterogeneity was not significant (*I*^2^= 0%, *P* = 0.52), and results were stable when sensitivity analyses were performed. We observed significant difference with simethicone plus NAC versus water. The rate of positive findings in simethicone plus NAC group was higher than that in water group (RR = 1.31, 95%CI: 1.12--1.53, *P* = 0.0006) \[[Figure 4](#F4){ref-type="fig"}\]. Heterogeneity was not significant (*I*^2^= 40%, *P* = 0.2). The resulting evidence was presented by using tool GRADEpro GDT online for every outcome. The level of evidence for simethicone versus water was moderate, because Liu *et al*.\[[@ref32]\] reported only precancerous lesions and early cancer, but not all lesions. The level of evidence of the other two studies was high \[[Table 3](#T3){ref-type="table"}\].

![Positive findings (simethicone vs water)](SJG-25-218-g002){#F2}

![Positive findings (simethicone + NAC vs simethicone). NAC: *N*-acetylcysteine](SJG-25-218-g003){#F3}

![Positive findings (simethicone + NAC vs water). NAC: *N*-acetylcysteine](SJG-25-218-g004){#F4}

###### 

Grade evidence profile of positive findings

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Certainty assessment                                                                 No. of patients     Effect        Certainty     Importance                                                                                                                                                   
  ------------------------------------------------------------------------------------ ------------------- ------------- ------------- ------------- ------------- ------ ------------------ ------------------ ------------------------ ----------------------------------------------- ---------- ----------
  Simethicone vs water for positive findings (follow-up: range 1-7 days)                                                                                                                                                                                                                            

  3                                                                                    Randomized trials   Not serious   Serious\*     Not serious   Not serious   None   270/1879 (14.4%)   235/1872 (12.6%)   RR 1.13 (0.82 to 1.55)   16 more per 1,000 (from 23 fewer to 69 more)    ⨁⨁⨁◯\      Critical
                                                                                                                                                                                                                                                                                         Moderate   

  Simethicone + NAC VS simethicone for positive findings (follow-up: range 1-7 days)                                                                                                                                                                                                                

  3                                                                                    Randomized trials   Not serious   Not serious   Not serious   Not serious   None   252/717 (35.1%)    265/783 (33.8%)    RR 1.02 (0.90 to 1.16)   7 more per 1,000 (from 34 fewer to 54 more)     ⨁⨁⨁⨁\      Critical
                                                                                                                                                                                                                                                                                         High       

  Simethicone + NAC vs water for positive findings (follow-up: range 1-7 days)                                                                                                                                                                                                                      

  2                                                                                    Randomized trials   Not serious   Not serious   Not serious   Not serious   None   98/134 (73.1%)     76/140 (54.3%)     RR 1.31 (1.12 to 1.53)   168 more per 1,000 (from 65 more to 288 more)   ⨁⨁⨁⨁\      Critical
                                                                                                                                                                                                                                                                                         High       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: Confidence interval; RR: Risk ratio, \*Liu (2017) reported only precancerous lesions and early cancer, not all lesions

### Total mucosal visibility score (TMVS) {#sec3-6}

All studies reported total mucosal visibility score, but only one of the studies presented it as number of excellent/adequate/inadequate scale, and one showed volume of flush used. We could not extract TMVS from either of them. Meanwhile, Monnory *et al*.\[[@ref31]\] reported total mucosal visibility score as mean + interquartile range (IQR), and the standard deviation was estimated from number, mean and range.\[[@ref33]\] Compared with water, simethicone displayed significant differences on TMVS with substantial heterogeneity (mean difference, MD = −3.62, (−4.65, −2.60), *P* \< 0.00001, *I*^2^= 67%) \[[Figure 5](#F5){ref-type="fig"}\]. In order to further explore the sources of heterogeneity, we conducted a sensitivity analysis. When removing the study by Monnory *et al*.,\[[@ref31]\] the heterogeneity reduced to *I*^2^= 52%, which potentially accounted for the source of heterogeneity. We speculated that the cause of high heterogeneity was estimated standard deviation, whereas the other three studies provided primary standard deviation. Though the heterogeneity was still high, the outcome was relatively robust. Simethicone plus NAC showed similar effect than water (MD = −3.29 (−4.38, −2.21), *P* \< 0.00001, *I*^2^= 60%) \[[Figure 6](#F6){ref-type="fig"}\]. We conducted a sensitivity analysis to look for heterogeneity. Removing the study by Asl *et al*.\[[@ref17]\] the heterogeneity reduced to low (*I*^2^= 28%), the meta-analysis result changed to: MD = −2.7 (−4.19, −1.22, *P* = 0.0004). It is assumed that the source of heterogeneity might be because the Asl\[[@ref17]\] study used dimethicone as an intervention while the other two studies used simethicone. Simethicone plus NAC showed better TMVS than simethicone alone (MD = −0.14 (−0.25, −0.03), *P* = 0.01, *I*^2^= 0%) without significant heterogeneity \[[Figure 7](#F7){ref-type="fig"}\]. GRADEpro GDT showed that the level of evidence was moderate for TMVS for the three outcomes \[[Table 4](#T4){ref-type="table"}\].

![Total mucosal visibility score (simethicone vs water)](SJG-25-218-g005){#F5}

![Total mucosal visibility score (simethicone + NAC vs water), NAC: *N*-acetylcysteine](SJG-25-218-g006){#F6}

![Total mucosal visibility score (simethicone + NAC vs simethicone), NAC =*N*-acetylcysteine](SJG-25-218-g007){#F7}

###### 

Grade evidence profile of total mucosal visibility score

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Certainty assessment                                                                     No. of patients     Effect        Certainty    Importance                                                                                                
  ---------------------------------------------------------------------------------------- ------------------- ------------- ------------ ------------- ------------- ------ ----- ----- ---- ------------------------------------------ ---------- ----------
  Simethicone vs water for mucosal visibility score (follow-up: mean 1 days)                                                                                                                                                                        

  4                                                                                        Randomized trials   Not serious   Serious^a^   Not serious   NOT SERIOUS   None   173   169   \-   MD 3.62 lower (4.65 lower to 2.6 lower)    ⨁⨁⨁◯\      Critical
                                                                                                                                                                                                                                         Moderate   

  Simethicone + NAC vs water for mucosal visibility score (follow-up: mean 1 days)                                                                                                                                                                  

  3                                                                                        Randomized trials   Not serious   Serious\*    Not serious   Not serious   None   123   124   \-   MD 3.29 lower (4.38 lower to 2.21 lower)   ⨁⨁⨁◯\      Critical
                                                                                                                                                                                                                                         Moderate   

  Simethicone + NAC vs simethicone for mucosal visibility score (follow up: mean 1 days)                                                                                                                                                            

  3                                                                                        Randomized trials   Not serious   Serious\*    Not serious   Not serious   None   665   726   \-   MD 0.14 lower (0.25 lower to 0.03 lower)   ⨁⨁⨁◯\      Critical
                                                                                                                                                                                                                                         Moderate   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Keeratichananont 2010\[[@ref26]\] designed 133.3 mg as dose of simethicone, Asl 2011\[[@ref17]\] designed 100 mg as dose of dimethicone, Song 2016\[[@ref5]\] designed 100 mg as dose of simethicone, Monrroy 2017\[[@ref31]\] designed 200 mg as dose of simethicone. CI: Confidence interval; RR: Risk ratio. \*Mucosa visibility scores were slightly different, dose of simethicone, and NAC were also different

### Procedure time {#sec3-7}

Five studies\[[@ref26][@ref27][@ref28][@ref30][@ref32]\] presented procedure time. For the included studies, one\[[@ref28]\] presented time as mean + 95%CI. The standard deviation was estimated from number, mean and 95%CI.\[[@ref33]\] Two of them\[[@ref27][@ref30]\] used seconds as unit, so we switched it into minutes. The procedure time in simethicone was shorter than that in water group (MD = −1.23 (−1.51, −0.96), *P* \< 0.00001, *I*^2^= 31%) \[[Figure 8](#F8){ref-type="fig"}\] without obvious heterogeneity. Compared with water, simethicone plus NAC showed no significant difference (MD = −0.81 (−2.06, −0.44), *P* = 0.21, *I*^2^= 0%) \[[Figure 9](#F9){ref-type="fig"}\] without obvious heterogeneity. GRADEpro GDT showed level of evidence was high on procedure time \[[Table 5](#T5){ref-type="table"}\].

![Procedure time (simethicone vs water)](SJG-25-218-g008){#F8}

![Procedure time (simethicone + NAC vs water). NAC =*N*-acetylcysteine](SJG-25-218-g009){#F9}

###### 

Grade evidence profile of procedure time

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Certainty assessment         No.of patients      Effect        Certainty     Importance                                                                                                  
  ---------------------------- ------------------- ------------- ------------- ------------- ------------- ------ ------- ------- ---- ------------------------------------------- ------- -----------
  Simethicone vs water                                                                                                                                                                     

  3                            Randomized trials   Not serious   Not serious   Not serious   Not serious   None   1,930   1,913   \-   MD 1.23 lower (1.51 lower to 0.96 lower)    ⨁⨁⨁⨁\   Important
                                                                                                                                                                                   High    

  Simethicone + NAC vs water                                                                                                                                                               

  2                            Randomized trials   Not serious   Not serious   Not serious   Not serious   None   64      63      \-   MD 0.81 lower (2.06 lower to 0.44 higher)   ⨁⨁⨁⨁\   Important
                                                                                                                                                                                   High    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: Confidence interval; MD: Mean difference

### Adverse events {#sec3-8}

Four studies\[[@ref5][@ref26][@ref29][@ref31]\] reported adverse events (AEs). Main AEs were nausea, vomiting and bloating. There was no significant difference in simethicone and water group (RR = 0.45, 95%CI: 0.2--1.0, *P* = 0.05, *I*^2^= 0%) \[[Figure 10](#F10){ref-type="fig"}\]. Heterogeneity was not significant. GRADEpro GDT showed level of evidence was high on AEs \[[Table 6](#T6){ref-type="table"}\].

![Adverse events (simethicone vs water)](SJG-25-218-g010){#F10}

###### 

Grade evidence profile of adverse events

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Certainty assessment                     No. of patients     Effect        Certainty     Importance                                                                                                                                         
  ---------------------------------------- ------------------- ------------- ------------- ------------- ------------- ------ -------------- --------------- ------------------------ ----------------------------------------------- ------- -----------
  Adverse events (follow-up: mean 1 day)                                                                                                                                                                                                      

  4                                        Randomized trials   Not serious   Not serious   Not serious   Not serious   None   7/237 (3.0%)   15/227 (6.6%)   RR 0.45 (0.20 to 1.00)   36 fewer per 1,000 (from 0 fewer to 53 fewer)   ⨁⨁⨁⨁\   Important
                                                                                                                                                                                                                                      High    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: Confidence interval; RR: Risk ratio

DISCUSSION {#sec1-4}
==========

Simethicone, dimethicone and NAC are widely used as anti-bubble premedication before gastroscopy, colonoscopy and capsule endoscopy.\[[@ref34][@ref35]\] The aim of this review was to summarize and evaluate the effect and safety of simethicone or dimethicone ± NAC as preprocedural preparation of gastroscopy. By synthesizing all extractable data from previous trials, this meta-analysis provides a better basis that we can depend on for choosing premedication. We included 10 studies comprising of 5,750 participants into the meta-analysis. Though allocation concealment and blinding of outcome data were unclear in three studies, quality assessment showed that the quality of included articles achieved the ")high-quality study.") Some data showed significant heterogeneity. We speculated that in the meta-analysis was due to different interventions, and in another that estimated standard deviation from mean + IQR. Unfortunately, we could not ascertain the cause of substantial heterogeneity of positive findings (simethicone vs water). However, sensitivity analysis showed that all outcomes remained robust.

Regarding our primary outcome of preprocedural effect of simethicone ± NAC, the result showed that simethicone plus NAC premedication as comparison with water had a significantly higher positive findings rate. Medium level of heterogeneity existed; the level of evidence was high, supporting our confidence of simethicone plus NAC as premedication. Simethicone plus NAC showed no superior effect compared with simethicone alone, accompanying with considerable heterogeneity and high level of evidence. Not only simethicone plus NAC, but also simethicone alone was statistically more effective than water for mucosal visibility, with substantial heterogeneity, whereas the evidence quality was moderate. Mucosal visibility by simethicone plus NAC was significantly better, than simethicone alone, with moderate level of evidence. However, the result did not maintain consistency when sensitivity analysis was performed. Mucosal visibility is one of the important elements for gastroscopy, especially for screening for early upper gastrointestinal cancer. Since early upper gastrointestinal neoplasia is superficial, detection of minor elevations or depressions in the mucosal surface and subtle changes in color is difficult when bubbles and foam exist in esophagus and stomach. Bubbles and foam may cover superficial and minor lesions, which can easily be missed during gastroscopic procedure. Simethicone plus NAC, as anti-bubble and mucolytic agents, is an appropriate option before gastroscopy. These defoamers and mucolytic agents are used widely in Japan and China. In our experience, adequate endoscopic visualization helps us screen entire upper gastrointestinal mucosa and increase the rate of positive findings. Procedure time in simethicone group was shorter than water without substantial heterogeneity. Mean procedure time in the included studies ranged from 5.1 to 10.5 min. The main cause for prolonged time is flushing time and aspiration. Actually, for patients without sedation, tolerability of the procedure might influence overall mucosal screening. Shorter procedure time may be suitable for patients with poor tolerance without sedation. However, there is considerable debate about procedure time. The study by Teh *et al*.\[[@ref36]\] in 2015 showed a threefold increase in findings for a with procedure time of \>7 min compared with those who were spending less time on their examination. A minimum 7-min procedure time for diagnostic EGD was recommended by European Society of Gastrointestinal Endoscopy in 2016.\[[@ref37]\] In our opinion, if the patient prefers unsedated procedure, we suggest taking oral simethicone ± NAC before gastroscopy in order to decrease flushing times and provide enough time to screen. If the patient prefers sedation, procedure time of at least 7 min will be better for first diagnostic EGD. Additionally, adverse events were also reported. The most common adverse events were nausea, vomiting and bloating, which were within the acceptable range. Simethicone did not result in more adverse events than water.

There are two meta-analyses published previously evaluating simethicone ± NAC with water within the past 5 years, as follows: Chen *et al*.\[[@ref38]\] and Sajid *et al*.\[[@ref39]\] TMVS of the meta-analysis is similar to both of them. Neither of them summarized and evaluated positive findings rate, procedure time and adverse events frequency. Chen *et al*.\[[@ref38]\] included 10 studies in 2014, 7 of which were excluded by us due to either poor information of design or simethicone combination with pronase. Sajid *et al*.\[[@ref39]\] included seven studies in 2018. But the data synthesis and analysis were performed on all included trials regardless of whether simethicone alone or simethicone plus NAC were used. All these items above may lead to a biased. We did not perform subgroup analyses of trials because of fewer number of included studies. In effect, compared with former studies,\[[@ref38][@ref39]\] TMVS was similar in this meta-analysis except for positive findings rate, procedure time and adverse events frequency, which are being reported in this meta-analysis.

Nevertheless, there are several limitations in this study. Like previous reviews, the main limitation of our meta-analysis is the number of included studies. Although 10 studies were included, no more than five studies could be combined together evaluated each outcome. We did not evaluate publication bias due to the small number of included studies. Potential publication bias might exist. Otherwise, very few negative results might cause bias as well. Secondly, four mucosal visibility scales and different dose of interventions were adopted in the included studies. Standard deviation was estimated in two studies which did not provide standard deviation. Because of these reasons, heterogeneity and inconsistency existed.

Interestingly, though simethicone is used in many procedures, its safety is a cause of concern is an issue. Fluid containing simethicone may remain inside an despite reprocessing.\[[@ref40]\] This could potentially foster result in microbial growth.\[[@ref41]\] Its potential harmful effect needs further investigation.

In conclusion, data from currently available RCTs provide a clear rationale for suggesting the use of simethicone plus NAC as premedication before gastroscopy. However, an agreed mucosal visibility scoring tool is needed, along with the flush volume to be used and notwithstanding assessment of safety that remains to be clarified.
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